Continuous vs. Intermittent ADT Therapy
Dr. Myers talks about continuous versus intermittent ADT for PCa. Click here to view.
Continuous vs. Intermittent ADT Therapy Read More »
Raduim-223 Drug Beneficial for Bone Metatasis Patients
Treatment with the investigational drug radium-223 (Alpharadin) is associated with significantly increased overall survival in patients with castration-resistant prostate cancer (CRPC), researchers reported at the American Society of Clinical Oncology 2012 annual meeting. Read More.
Raduim-223 Drug Beneficial for Bone Metatasis Patients Read More »
Survival Better with Continuous ADT
CHICAGO—Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer (PCa), but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting. Read More
Survival Better with Continuous ADT Read More »
New Therapies
New Therapies for Prostate Cancer: The Practicalities Jeannette Y. Wick, RPh, MBA Published Online: Tuesday, May 15, 2012 Click here to view article.
Management of Metastatic Castration-resistant Prostate Cancer
Management of Metastatic Castration-resistant Prostate Cancer Abstract The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forwards in the last two years, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel and abiraterone acetate) and a significant delay in skeletal-related events observed with denosumab. … Click here for more.
Management of Metastatic Castration-resistant Prostate Cancer Read More »